Strongest human evidence: easing poor leg-vein circulation and, applied to skin, improving wound healing, scars, and wrinkles — tied to plant compounds that boost collagen and small blood vessels. Memory and longevity claims are least supported. Main safety concern: rare liver injury after weeks of use; avoid in pregnancy and liver disease. (Full Review)

Protocol

Oral Dose (Circulatory)

60–120 mg/day TECA

Standardized titrated extract, divided into two or three doses

Topical (Skin)

Cream/gel once or twice daily

Gotu Kola or asiaticoside, applied for 8–12 weeks; better-supported route for skin outcomes

Standardization

Standardized TECA, not whole-herb

Standardized to triterpene content; whole-herb powder, tea, or leaves deliver variable active content

Time to effect

Venous Symptoms

Several weeks

Circulatory symptom improvement over several weeks of consistent oral dosing

Skin & Wrinkles

8–12 weeks

Topical skin and wrinkle benefits accrue over 8–12 weeks

Mood & Alertness

~1 hour

Any acute mood/alertness effect appears within about an hour but is transient

Benefits

High: Improvement of chronic venous insufficiency symptoms

Medium: Wound healing and scar improvement; reduction of facial wrinkles and improved skin hydration

Low: Acute improvement in alertness and mood; reduction of anxiety symptoms; stabilization of atherosclerotic plaque

Speculative: Neuroprotection and cognitive aging support; general longevity and vitality

Contraindications

Pregnancy and breastfeeding

Active or chronic liver disease, or history of drug-induced liver injury

Surgery scheduled within ~2 weeks

Known Apiaceae-family or prior Gotu Kola allergy

Key Interactions

Sedatives and CNS depressants (benzodiazepines, Z-drugs, barbiturates, opioids, alcohol)

Hepatotoxic drugs (high-dose acetaminophen/paracetamol, certain statins, methotrexate, isoniazid)

Diabetes medications (insulin, sulfonylureas, metformin)

Diuretics and antihypertensives

OTC sedating antihistamines (diphenhydramine, doxylamine)

Sedative or hepatotoxic supplements (valerian, kava, melatonin, Bacopa monnieri, ashwagandha)

Cholinesterase inhibitors (donepezil, rivastigmine)

Risk & Side Effects

High: Gastrointestinal upset

Medium: Hepatotoxicity; contact dermatitis

Low: Sedation and drowsiness

Speculative: Reproductive and pregnancy-related risk; possible carcinogenicity concern from topical overuse

Monitoring

Marker	Target	Why
ALT (alanine aminotransferase)	~10–26 U/L	Detects liver-cell stress, the herb's main serious risk
AST (aspartate aminotransferase)	~10–26 U/L	Complements ALT in detecting liver injury
Bilirubin (total)	~0.3–1.0 mg/dL	Flags impaired liver clearance / jaundice
ALP (alkaline phosphatase)	~40–90 U/L	Helps distinguish cholestatic (bile-flow) liver injury
Fasting glucose	~75–90 mg/dL	Screens for additive glucose effects if combined with diabetes drugs

Cadence: Baseline before starting, then roughly every 4–8 weeks during sustained oral use (e.g., baseline, 4 weeks, 8 weeks), and promptly if symptoms of liver stress appear

Qualitative Assessment

Leg symptoms (for venous use): heaviness, swelling, and aching — improvement over weeks signals benefit
Skin and scar appearance (for topical use): wrinkle visibility, hydration, and scar texture over 8–12 weeks
Mood and alertness: subjective calm, alertness, or anxiety levels, especially in the hour after dosing
Tolerability signals: nausea or stomach upset, drowsiness, and any skin reaction with topical use
Warning signs prompting immediate discontinuation: unusual fatigue, dark urine, abdominal pain, or yellowing of the skin or eyes

Gotu Kola for Health & Longevity

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment